Record Financial Performance:Parsons Corporation reported record results for total revenue ($1.8 billion), organic revenue growth (26%), net income, adjusted EBITDA, and operating cash flow for Q3 2024. This marks the 11th consecutive quarterly record for revenue and 12th for adjusted EBITDA.
Strong Growth Across Segments:Both business segments experienced double-digit revenue growth, with Federal Solutions growing by 42% and Critical Infrastructure by 10%. The company achieved over 20% organic growth for the sixth consecutive quarter.
Increased Guidance:Due to strong performance and successful acquisitions, Parsons raised its full-year revenue and adjusted EBITDA guidance, projecting revenue growth of 23% and adjusted EBITDA growth of 30% at the midpoint.
Strategic Acquisitions:The acquisition of BlackSignal Technologies and a definitive agreement to acquire BCC Engineering are expected to enhance Parsons' capabilities and geographical footprint, contributing significantly to future revenue.
Healthy Backlog and Book-to-Bill Ratio:The company reported a book-to-bill ratio of 1.0x, indicating a solid pipeline of future work, with $8.8 billion in backlog and $13 billion in awarded but not booked contracts.

Negatives:

Margin Pressures in Critical Infrastructure:The Critical Infrastructure segment experienced a decline in adjusted EBITDA margin due to a write-down on a legacy program, although pro forma margins excluding this charge would have been more favorable.
Recompete Risks:There are concerns regarding the potential recompete of a significant confidential contract, which could impact future revenue. The company anticipates typical runoff of programs and a recompete range of 5% to 15% for 2025.
Fluctuations in Contract Performance:The company acknowledged fluctuations in contract performance, particularly in the Critical Infrastructure segment, which may affect future profitability until legacy programs are fully wrapped up.
Hiring Challenges in Specialized Areas:While overall hiring has been strong, there are challenges in recruiting for cleared positions within the Federal Solutions segment, which may impact growth in that area.

schrts.co

SharpCharts | StockCharts.com

NVDA daily sts going get

Posted by kingpin15 on 14th of Jan 2025 at 03:35 pm

NVDA daily sts going get sold, domino's keep falling

Looks like a slightly incomplete STS update today. 25 on ...

Posted by kingpin15 on 13th of Jan 2025 at 08:06 pm

BKR pushing 2008 highs here.

DJT hod

Posted by kingpin15 on 13th of Jan 2025 at 03:57 pm

took my eyes off the coil, she blew today, damn!

Zuck was outspoken about AAPL with Rogan interview on Friday ...

Posted by kingpin15 on 13th of Jan 2025 at 03:41 pm

admin changes and he changes to suit his needs

UPRO high performance goes long....78min

Posted by kingpin15 on 13th of Jan 2025 at 03:21 pm

UPRO high performance goes long....78min

https://schrts.co/bryyQeuS Fractyl Health (NASDAQ: GUTS)has announced promising

Posted by kingpin15 on 13th of Jan 2025 at 12:44 pm

https://schrts.co/bryyQeuS

Fractyl Health (NASDAQ: GUTS)has announced promising initial results from the REVEAL-1 cohort of its REMAIN-1 study, showing successful weight maintenance after GLP-1 drug discontinuation and Revita procedure. The first patient maintained a 15% total body weight loss one month after stopping tirzepatide and receiving the Revita treatment, compared to typical 3% weight regain within four weeks of GLP-1 discontinuation.

The company reports strong enrollment progress in the REMAIN-1 pivotal study, with over 100 patients enrolled across 8 clinical sites in less than 4 months, demonstrating high demand from both patients and physicians. The study's mid-point analysis remains on track for Q2 2025. Full REVEAL-1 cohort data presentation is expected in Q1 2025, following slight delays due to holiday scheduling.

schrts.co

SharpCharts | StockCharts.com

PSNL’s oncology diagnostic platform, which

PSN Daily

Posted by kingpin15 on 13th of Jan 2025 at 11:44 am

PSNL’s oncology diagnostic platform, which combines assays with a valuable database, is only increasing in value as the company’s revenue grows, and this is validated by multiple strategic collaborations with larger companies – including a cash infusion that will help bridge the company to profitability.